19 results about "Epitope vaccine" patented technology

The application discloses a SARS-CoV-2 epitope type vaccine multi-epitope combination and application, and belongs to the technical field of coronavirus vaccine research and development.The first aspect of the application relates to a fusion protein, which comprises in sequence: (a) a SARS-CoV-2 spike protein receptor binding domain or a functional fragment thereof; (b) a T cell epitope domain, comprising: a CTL epitope cluster, the CTL epitope cluster comprising at least one CD8+ T cell epitope polypeptide selected from SEQ ID NO: 1-15; and (c) an immunoglobulin Fc domain.The application adopts a tandem strategy of immunodominant epitopes + conserved epitopes, predicts high-affinity T cell epitopes by computational biology methods, evaluates the HLA restriction in different populations, introduces a flexible linker peptide for optimization design, evaluates the immune effect difference of different combinations through in vitro and animal models, analyzes the synergistic or competitive relationship between epitopes, and optimizes the vaccine design.Through systematic comparison of the immunological effect difference of different epitope combinations and the adaptability to various vaccine platforms, the application establishes an optimized safe, efficient, broad-spectrum and long-acting multi-epitope vaccine design strategy, and has significant application value and important transformation value.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

The invention relates to an HIV (Human Immunodeficiency Virus) nanoparticle vaccine. According to the invention, through a structural biology strategy and a nanoparticle vaccine platform, immunogens with stable conformations are respectively designed for MPER and CD4bs, and are respectively displayed through virus-like particles (VLP), and finally, a combined double-epitope vaccine (Cocktail) is constructed. The immune effect of the vaccine in a mouse model finds that the vaccine can induce MPER and CD4bs double-target specific antibodies and stimulate the neutralizing activity on multi-subtype HIV pseudoviruses, and the broad spectrum is good.

According to the invention, dominant antigen epitopes of main outer membrane proteins OspA, OspB and OspC of borrelia burgdorferi are screened out, and a multi-epitope fusion vaccine containing the epitopes and application are constructed. The vaccine design not only improves the specificity and immunogenicity of the antigen. Compared with a traditional antigen epitope screening and construction strategy, the method has the advantages that the cycle is shortened, the cost is reduced, meanwhile, the limitations of many and complex antigens, large toxic and side effects and the like of a traditional vaccine are overcome, the operation process is simplified, the method is more suitable for large-scale epitope screening, popularization and application, and a new thought and strategy are provided for research and development of borrelia burgdorferi vaccines.

Compositions of peptides modified to enhance HLA binding or T cell recognition while preserving reactivity to target neoepitopes enhance the activation of neoantigen-specific T cells. The method of use involves treating cancer by administering one or more of these peptides, which are produced by computer modeling.

The invention discloses an avian leukosis tetravalent epitope mRNA vaccine and application, and belongs to the technical field of immunology and biology. According to epidemic strains of A, B, J and K subgroup avian leukosis viruses in recent 10 years, epitopes with relatively high antigenicity and conservative property in surface proteins (gp85 gene coding) are screened and connected in series, so that immune escape caused by self gene mutation of the avian leukosis viruses is avoided, the protection range is wider, and the kit has a good application prospect. And a molecular adjuvant is also added into an mRNA vaccine sequence to enhance the cellular immunity of the vaccine, so that the problem of low antigenicity of other vaccines is solved. Compared with purification investment, the vaccine has the advantages that the capital cost is saved by more than 50%, the consumption of time, manpower and material resources is greatly reduced, and the vaccine has a good application prospect.

The invention belongs to the technical field of microbial immunity and DNA vaccines, and particularly relates to a preferred epitope peptide of a Crimean-Congo hemorrhagic fever virus envelope glycoprotein C terminal (CCHFV Gc), a tandem multi-epitope vaccine, an expression vector and application. The preferable epitope peptide is composed of any one amino acid sequence as shown in SEQ ID NO.1-SEQ ID NO.21, and the preferable epitope peptide has high affinity, strong immunogenicity and interspecific amp; and an intraspecific conservative preferred epitope. Preferably epitopes are connected in series through a linker to synthesize a series multi-epitope vaccine, the series multi-epitope vaccine enters cells to be expressed to form recombinant protein, then T lymphocytes are activated, and cellular immune response is induced. The in-vivo vaccine evaluation of animals is carried out by using the tandem multi-epitope vaccine, and it is proved that the vaccine can effectively induce anti-CCHFV specific cellular immune response and the application safety in BALB / c mice. The invention is helpful for understanding the immunobiology of CCHFV Gc and perfecting the epitope vaccine design for the virus in the future.

The invention discloses a streptococcus pneumoniae PsaA protective epitope peptide, a vaccine and a preparation method and application thereof, the nucleotide sequence of the epitope peptide is shown as SEQ ID NO.1, a novel epitope vaccine ZnuA-PsaA-Loop90 (for short, ZPL90) is successfully constructed based on the epitope, after the vaccine is inoculated, an anti-Loop90 antibody can be efficiently induced in a mouse, the mouse can be effectively protected from being infected with streptococcus pneumoniae, and the streptococcus pneumoniae PsaA protective epitope peptide can be used for preparing the vaccine. Good application prospects are realized.

The invention discloses a gB, gH / gL and K8.1 multi-epitope DNA (deoxyribonucleic acid) vaccine for preventing KSHV (Kaposi's sarcoma associated herpes virus), and relates to the technical field of vaccines, in particular to a gB, gH / gL and K8.1 multi-epitope DNA vaccine for preventing KSHV infection, which is delivered by adopting a nano-carrier beta-CD-PEI, and simultaneously delivers a sulfo-modified small-fragment nucleic acid adjuvant, so that the KSHV infection can be effectively prevented and treated. The multi-epitope DNA vaccine mainly comprises four plasmids with His tags, the four plasmids are pcDNA3.1 (+)-gB-his, pcDNA3.1 (+)-K8.1-his, pcDNA3.1 (+)-gH-his and pcDNA3.1 (+)-gL-his, the four plasmids are combined on beta-CD-PEI through electrostatic adsorption, an adjuvant CPGodn1826 is adsorbed, and the KSHV nano multi-epitope DNA vaccine which is stable, high in delivery efficiency and good in immunogenicity is formed. The invention further provides a construction method of the DNA nano vaccine, the nano vaccine is characterized, and the immune effect is verified in a mouse body. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a relatively great application prospect.

This invention relates to the field of biotechnology and provides an antigenic epitope of the parainfluenza virus type 5 F protein, a monoclonal antibody, and its applications. 135 AAILNLKNAIQKTNAAVADVVQA 157 Furthermore, a monoclonal antibody that specifically recognizes this antigenic epitope is provided. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The discovery of this epitope provides a new target for the development of PIV5 diagnostic reagents. Peptide antigens can be designed and synthesized based on this epitope to develop highly specific ELISA diagnostic kits. Simultaneously, this epitope can be used as a candidate epitope for the design of multi-epitope vaccines, providing a new strategy for the prevention and control of PIV5.

The invention belongs to the technical field of biological medicines, and particularly relates to a Brucella recombinant multi-epitope vaccine and application thereof. The invention provides a recombinant multi-epitope vaccine protein of Brucella. The vaccine protein is a first vaccine variant rBMEV1 or a second vaccine variant rBMEV2. Results of embodiments prove that the vaccine provided by the invention can excite strong cross immune response aiming at main pathogenic species (such as sheep species, cattle species and pig species) of Brucella. Animal experiments prove that the antibody can induce a high-level and lasting specific antibody, can obviously activate response of CD4 + and CD8 + T cells and corresponding cell factors, and has good safety at the same time. According to the invention, the problems of narrow protection spectrum, dependence on exogenous adjuvants, single immune type and the like of the traditional brucella vaccine are solved, and a new generation of efficient, broad-spectrum and safe candidate vaccine strategy is provided for prevention and control of brucellosis.

The invention provides a preparation method of a novel human / mouse cross-reactive anti-PD-1 candidate vaccine, and belongs to the technical field of candidate vaccine preparation. The candidate vaccine obtained by the preparation method can inhibit combination of PD-1 and PD-L1, can reactivate depleted T cells and break the tumor microenvironment of immunosuppression, and meanwhile, the epitope vaccine is combined with HBc VLPs to stimulate generation of strong T cell immunity, so that generation and development of tumor cells are inhibited in two aspects.

This application relates to an HIV nanoparticle vaccine. The invention utilizes structural biology strategies and a nanoparticle vaccine platform to design stable conformations of immunogens targeting MPER and CD4bs, respectively, and displays them using virus-like particles (VLPs), ultimately constructing a combined dual-epitope vaccine (Cocktail). Immunization in a mouse model revealed that this vaccine can induce dual-target specific antibodies against MPER and CD4bs, and exhibits broad-spectrum neutralizing activity against multiple HIV pseudoviruses.

The invention discloses a toxoplasma gondii CTL epitope peptide identification method and application. The toxoplasma gondii CTL epitope peptide identification method comprises the following steps: constructing a toxoplasma gondii infection model of an HLA-A * 0201 transgenic mouse; capturing a natural peptide fragment combined with the HLA-A * 0201 molecule from the spleen lymphocyte surface of the infected model mouse through a weak acid elution method; analyzing the captured peptide fragment by adopting a liquid chromatography-tandem mass spectrometry technology, and screening a toxoplasma gondii-sourced specific peptide fragment based on a toxoplasma gondii protein database; through an in-vitro protein renaturation experiment, the binding capacity of the screened candidate peptide fragment and the HLA-A * 0201 molecule is verified; a TAP defect type T2 lymphoblastic cell model is adopted, and the binding stability of the candidate peptide fragment and the HLA-A * 0201 molecule is verified through a fluorescence index. According to the method, through a progressive screening strategy that after natural peptide group screening, a NetMHCpan-4.1 algorithm is adopted for filtering and eliminating host homology, in-vitro pMHC-I renaturation verification and T2 cell binding stability detection are carried out, the clinical transformation value of epitope screening is remarkably improved, and high-confidence candidate molecules are provided for toxoplasma gondii multi-epitope vaccine design.

This invention discloses a method for specifically recognizing antigen epitopes. 16 AQTGYAPV 23 This invention relates to a monoclonal antibody D3-mAb against porcine rotavirus and its applications, belonging to the field of antibody bioengineering technology. The monoclonal antibody D3-mAb specifically binds to the VP8 protein of porcine rotavirus and exhibits neutralizing activity; its amino acid sequence is shown in SEQ ID NO. 8. This invention screened a monoclonal antibody D3 with neutralizing activity against the VP8 protein, and subsequently identified the neutralizing antigenic epitope. 16 AQTGYAPV 23 Recognized by D3-mAb, sequence comparison analysis of currently circulating PoRVA strains revealed that this antigenic epitope is absolutely conserved. Furthermore... 16 AQTGYAPV 23 The epitope, located on the surface of the VP8 protein, interacts with the antibody's variable region via six hydrogen bonds. This invention provides a novel approach for designing novel epitope vaccines and antiviral strategies, and the provided monoclonal antibody holds promise for development into a biotherapeutic agent and diagnostic agent for porcine rotavirus infection.

The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing Seneca virus epitope and application of Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that Seneca virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the Seneca virus antigen epitopes, so that efficient and soluble expression of a target antigen in escherichia coli can be realized; the protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralizing Seneca virus antibody, improves the immune efficacy, and has the potential of becoming a Seneca multi-epitope vaccine.

The application discloses a type 2 GAstV capsid protein monoclonal antibody and an antigen epitope peptide thereof. The monoclonal antibody is prepared after a mouse is immunized with a type 2 goose astrovirus capsid protein GAstV Cap as an antigen and is named 1F1. The monoclonal antibody 1F1 comprises a heavy chain variable region and a light chain variable region, and the amino acid sequences are shown in SEQ ID No. 3 and SEQ ID No. 5 in sequence. In order to determine the B cell antigen epitope of the screened monoclonal antibody, a GAstV Cap truncated fusion protein is constructed, and antigen recognition epitopes are determined through indirect ELISA and Western blotting experiments, so that the monoclonal antibody is screened step by step until the shortest linear epitope recognized by the monoclonal antibody is determined, and the amino acid sequence is shown in SEQ ID No. 10. Therefore, the monoclonal antibody and the antigen epitope thereof in the application can be applied to the research on the structure and function of the GAstV capsid protein, serological diagnostic tools and the preparation of epitope vaccines.

The invention discloses a method for rapidly constructing a broad-spectrum cross protection type IBV nested epitope vaccine. According to the method, computer simulation docking and in-vitro immunological screening are combined, conservative and effective antigen epitopes are rapidly and accurately identified from a large number of strain sequences, the antigen epitopes are embedded into a virus genome S1 structural domain on the basis of a reverse genetic technology, and therefore the nested epitope vaccine strain rSczy3C100-S1T is obtained. The problems that an existing IBV vaccine is narrow in immune protection spectrum, poor in cross protection and long in research and development period are solved, candidate vaccines aiming at emerging strains can be constructed in a short time, and the vaccine development efficiency and broad-spectrum protection capacity are remarkably improved.